
Deep Brain Stimulators (DBS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Description
Deep Brain Stimulators (DBS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Deep Brain Stimulators (DBS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Deep Brain Stimulators (DBS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
A Deep Brain Stimulators (DBS) is a device that is comprised of a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation through surgically implanted electrodes to specific targets in the brain. DBSs are commonly used to treat movement disorders as well as neuropsychiatric disorders.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Deep Brain Stimulators (DBS) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Deep Brain Stimulators (DBS) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Deep Brain Stimulators (DBS) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
131 Pages
- Deep Brain Stimulators (DBS) Overview
- Deep Brain Stimulators (DBS) - Pipeline Products by Stage of Development
- Deep Brain Stimulators (DBS) - Pipeline Products by Segment
- Deep Brain Stimulators (DBS) - Pipeline Products by Territory
- Deep Brain Stimulators (DBS) - Pipeline Products by Regulatory Path
- Deep Brain Stimulators (DBS) - Pipeline Products by Estimated Approval Date
- Deep Brain Stimulators (DBS) - Ongoing Clinical Trials
- Deep Brain Stimulators (DBS) Companies - Pipeline Products by Stage of Development
- Deep Brain Stimulators (DBS) - Pipeline Products by Stage of Development
- Abbott Laboratories Company Overview
- Adaptive Neuromodulation GmbH Company Overview
- Adept Neuro SA Company Overview
- Aleva Neurotherapeutics SA Company Overview
- Allegheny Health Network Company Overview
- Amber Therapeutics Ltd Company Overview
- Baylor College of Medicine Company Overview
- Boston Scientific Corp Company Overview
- Clinatec Company Overview
- Deep Brain Innovations, LLC Company Overview
- Deep Brain Stimulation Technologies Pty Ltd Company Overview
- Enspire DBS Therapy Inc Company Overview
- Hangzhou General Stim Biotechnology Co Ltd Company Overview
- Hangzhou Promise Medical Technology Co Ltd Company Overview
- Louisiana State University Company Overview
- Massachusetts General Hospital Company Overview
- Medtronic Plc Company Overview
- National Cheng-Kung University Hospital Company Overview
- NeuroOne Medical Technologies Corp Company Overview
- NeuroPro Technologies Inc Company Overview
- Neurosigma Inc Company Overview
- Newronika s.r.l. Company Overview
- Nexeon MedSystems Inc Company Overview
- Nia Therapeutics Inc Company Overview
- Oxford University Innovation Ltd Company Overview
- Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview
- St. Jude Medical LLC Company Overview
- Stanford University Company Overview
- Sunnybrook Health Sciences Centre Company Overview
- UConn School of Medicine Company Overview
- University of California Los Angeles Company Overview
- University of California San Francisco Company Overview
- University of Central Florida Company Overview
- University of Florida Company Overview
- University of Illinois Company Overview
- University of Milan Company Overview
- University of Minnesota Company Overview
- University of Oxford Company Overview
- University of Pittsburgh Company Overview
- University of Rochester Company Overview
- University of South Florida Company Overview
- Aug 20, 2024: Self-Adjusting Brain Pacemaker May Help Reduce Parkinson's Disease Symptoms
- Aug 19, 2024: Taming Parkinson's Disease with Intelligent Brain Pacemakers
- Aug 15, 2024: NIH Funds UK's Groundbreaking DBS-Plus Trial for Parkinson's
- Aug 12, 2024: Medtronic Receives Landmark FDA Approval for Asleep Deep Brain Stimulation Surgery
- Aug 04, 2024: Medtronic Receives Humanitarian Device Exemption (HDE) For Percept RC With BrainSense
- Jul 15, 2024: Medtronic Neuromodulation Receives Humanitarian Device Exemption (HDE) For Percept PC BrainSense Neurostimulator Model - B35200
- Jul 15, 2024: Medtronic Receives Humanitarian Device Exemption For Reclaim DBS System
- Jul 15, 2024: Medtronic Neuromodulation Receives Humanitarian Device Exemption (HDE) For Activa Dystonia Therapy System
- Jul 10, 2024: Medtronic Receives Humanitarian Device Exemption (Hde) For Reclaim DBS System
- Jul 10, 2024: Medtronic Neuromodulation Receives Additional Humanitarian Device Exemption (HDE) Clearance for Percept PC BrainSense Neurostimulator Model - B35200
- Jul 10, 2024: Medtronic Neuromodulation Obtains Additional Humanitarian Device Exemption (HDE) Clearance for the Activa Dystonia Therapy System
- Jun 18, 2024: New Technology Allows Researchers to Precisely, Flexibly Modulate Brain
- Jun 13, 2024: Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
- Jun 13, 2024: Medtronic Confirms Global Layoffs
- Jun 06, 2024: Medtronic Neuromodulation obtains Additional Humanitarian Device Exemption (HDE) clearance for Activa Dystonia Therapy System
- May 16, 2024: Medtronic Neuromodulation Receives Additional 510(K) Clearance For Percept PC BrainSense Neurostimulator Model - B35200
- May 13, 2024: Medtronic Neuromodulation receives additional 510(k) clearance for Activa Dystonia Therapy System
- May 08, 2024: Medtronic Neuromodulation Receives Additional Humanitarian Device Exemption (HDE) clearance for Activa Dystonia Therapy System
- May 08, 2024: Medtronic Receive Additional Humanitarian Device Exemption (HDE) clearance for Reclaim DBS System
- May 08, 2024: Medtronic Receives Additional Humanitarian Device Exemption (HDE) clearance for Percept PC Neurostimulator DBS System
- Apr 23, 2024: Medtronic Neuromodulation Receives Additional Humanitarian Device Exemption (HDE) Clearance for Activa Dystonia Therapy System
- Apr 23, 2024: Medtronic ) Receives Humanitarian Device Exemption (HDE) for Percept RC With BrainSense
- Apr 15, 2024: Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw
- Apr 12, 2024: Rice team demonstrates miniature brain stimulator in humans
- Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference
- Mar 04, 2024: Medtronic Neuromodulation Receives Additional Humanitarian Device Exemption (HDE) For Activa Dystonia Therapy System
- Mar 04, 2024: Medtronic Receives Additional Humanitarian Device Exemption (HDE) For Reclaim DBS System
- Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company
- Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering
- Feb 15, 2024: Stephen Agostini Named UCLA's Vice Chancellor and Chief Financial Officer
- Feb 14, 2024: UT Health San Antonio doctors among first to implant rechargeable deep brain stimulation device
- Jan 28, 2024: Medtronic Receives An Additional HDE Clearance for Reclaim DBS System
- Jan 26, 2024: Abbott scores FDA approval for small, long lasting rechargeable DBS
- Jan 11, 2024: AHN Team Performs Region's First Deep Brain Stimulation Therapy to Treat Opioid Addiction
- Jan 11, 2024: Nexalin Technology Unveils Next-Generation HALO Clarity
- Jan 09, 2024: US FDA approves Medtronic's Percept RC neurostimulator
- Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
- Dec 05, 2023: Medtronic Receives CE Mark for the Percept RC Rechargeable DBS Neurostimulator With BrainSense Technology
- Dec 04, 2023: NeuroPace to Leverage the Power of its RNS System's Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
- Dec 04, 2023: UCF Welcomes Alum and Distinguished Military Leader as Associate VP of Federal Affairs
- Nov 16, 2023: Neuroone Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
- Nov 02, 2023: Medtronic Obtains Additional Humanitarian Device Exemption (HDE) Clearance for Activa Dystonia Therapy System
- Nov 02, 2023: Medtronic Receives Additional HDE Clearance for Reclaim DBS System
- Nov 02, 2023: Medtronic Neuromodulation Receives Additional HDE Clearance for Percept PC BrainSense
- Nov 02, 2023: Medtronic Neuromodulation Receives Additional HDE Clearance for Percept PC BrainSense
- Oct 17, 2023: NeuroPace Announces RNS System Enhancements Designed to Streamline Care
- Oct 12, 2023: Medtronic Neuromodulation Obtains Additional Humanitarian Device Exemption (HDE) Clearance for Percept PC BrainSense
- Oct 12, 2023: Medtronic Obtains Additional Humanitarian Device Exemption (HDE) Clearance for Activa Dystonia Therapy System
- Sep 07, 2023: UCF Names Saiful Khondaker as Interim Assistant Vice President for Research Advancement
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.